Hoth Therapeutics just dropped some wild early results: every single patient in their cancer drug trial responded to treatment, and disease severity was cut in half by week 6. People even saw improvements as early as week 3! The stock’s been a bit rocky lately, but analysts are still bullish with a $6.50 price target. If this keeps up, Hoth could be the next big biotech comeback story. Would you take a chance on this stock? #Health #BodyHealth #CancerResearch